Switzerland· 70278002
Saphnelo 120 mg/0.8 ml, Injektionslösung in einem Fertigpen
A anifrolumab product containing anifrolumabum, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Anifrolumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG11 (anifrolumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Anifrolumab · ATC L04AG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of anifrolumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- Switzerland: $42.60 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Anifrolumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$42.60
The record
At a glance
Swissmedic (Switzerland)- Active substance
- anifrolumabum
- Manufacturer
- AstraZeneca AG
- Country
- Switzerland (CH)
- ATC code
- L04AG11
- ATC class
- Anifrolumab
- Defined daily dose
- 10.7 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76807027800234 StkCHF 990.6
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anifrolumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSAPHNELOAstraZeneca AB, Södertälje
- BelgiumSaphnelo 120 mgAstraZeneca
- FinlandSaphneloAstraZeneca AB
- IrelandSaphnelo 120 mg solution for injection in pre-filled penAstraZeneca AB
- IcelandSaphneloAstraZeneca AB*
- NetherlandsSaphnelo 120 mg oplossing voor injectie in een voorgevulde penAstraZeneca AB
- PolandSaphneloAstraZeneca AB
- SwedenSaphnelo 120 mg Injektionsvätska, lösning i förfylld injektionspennaAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Saphnelo
- Liechtenstein · Saphnelo
- Norway · Saphnelo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f46733c3-02be-42a4-a11d-1aeb14af5a80 GET /v1/drugs/f46733c3-02be-42a4-a11d-1aeb14af5a80?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "anifrolumabum",
"valid_from": "2026-08-01",
"limitations": "[{\"description\":\"Erstverordnung durch FachärztInnen für Klinische Immunologie und Rheumatologie.<br>\\nNach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nZur Behandlung von erwachsenen Patienten mit mittelschwerem bis schwerem systemischem Lupus erythematodes (SLE) zusätzlich zur Standardtherapie.\\nDie Wirksamkeit / Zweckmässigkeit von Saphnelo muss spätestens nach 6 Monaten durch den aktuell behandelnden Arzt zu Handen des Vertrauensarztes reevaluiert werden.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"22162.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\"}]",
"galenic_form": "Inj Lös 120 mg/0.8 ml Fertpen",
"therapeutic_area": null,
"sl_inclusion_date": "2026-08-01",
"self_retention_pct": 10
}See everything about anifrolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.